Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Reform Bill Will Keep Firms Scrambling To Stay Ahead On Safety Issues

Executive Summary

Pharmaceutical companies need to immediately begin assessing whether their drugs are subject to the risk evaluation and mitigation strategies provisions of the FDA Amendments Act, participants were warned during a Food and Drug Law Institute audioconference on the new law, Oct. 4

You may also be interested in...



Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps

Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline

Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps

Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline

Will FDA/CMS Parallel Review Idea Make Headway This Time?

The possibility of simultaneous FDA and CMS evaluations of new health products is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel